Cargando…
Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy
BACKGROUND: The objective of this study is to provide comprehensive overviews of patient-reported urinary symptoms for long-term prostate cancer survivors treated with radiation therapy and for untreated, healthy men. METHODS: We performed a population-based cross-sectional study using a study-speci...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670502/ https://www.ncbi.nlm.nih.gov/pubmed/23632483 http://dx.doi.org/10.1038/bjc.2013.180 |
_version_ | 1782271860054949888 |
---|---|
author | Olsson, C E Pettersson, N Alsadius, D Wilderäng, U Tucker, S L Johansson, K-A Steineck, G |
author_facet | Olsson, C E Pettersson, N Alsadius, D Wilderäng, U Tucker, S L Johansson, K-A Steineck, G |
author_sort | Olsson, C E |
collection | PubMed |
description | BACKGROUND: The objective of this study is to provide comprehensive overviews of patient-reported urinary symptoms for long-term prostate cancer survivors treated with radiation therapy and for untreated, healthy men. METHODS: We performed a population-based cross-sectional study using a study-specific postal questionnaire assessing symptoms among 1007 men consecutively treated at the Sahlgrenska University Hospital, Göteborg, Sweden from 1993–2006 (primary or salvage external beam radiation therapy (EBRT) or EBRT and high-dose rate brachytherapy). We also randomly recruited 350 non-pelvic-irradiated matched control men from the Swedish Total Population Register. Symptom prevalence and prevalence ratios were computed. RESULTS: Survey participation rate was 89% (874/985) for eligible survivors and 73% (243/332) for eligible controls. Median time from treatment to follow-up was 5 years (range, 1–14 years). Among the 21 investigated symptoms reflecting obstruction, frequency, urgency, pain and incontinence, we found significantly higher prevalence compared with controls for 9 symptoms in the EBRT group, 10 in the EBRT+brachytherapy group and 5 in the salvage EBRT group. The prevalence for a majority of the symptoms was stable over time. CONCLUSION: The presented toxicity profiles provide a thorough understanding of patient-reported urinary symptoms that can assist in developing personalised therapy for prostate cancer. |
format | Online Article Text |
id | pubmed-3670502 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-36705022014-05-28 Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy Olsson, C E Pettersson, N Alsadius, D Wilderäng, U Tucker, S L Johansson, K-A Steineck, G Br J Cancer Clinical Study BACKGROUND: The objective of this study is to provide comprehensive overviews of patient-reported urinary symptoms for long-term prostate cancer survivors treated with radiation therapy and for untreated, healthy men. METHODS: We performed a population-based cross-sectional study using a study-specific postal questionnaire assessing symptoms among 1007 men consecutively treated at the Sahlgrenska University Hospital, Göteborg, Sweden from 1993–2006 (primary or salvage external beam radiation therapy (EBRT) or EBRT and high-dose rate brachytherapy). We also randomly recruited 350 non-pelvic-irradiated matched control men from the Swedish Total Population Register. Symptom prevalence and prevalence ratios were computed. RESULTS: Survey participation rate was 89% (874/985) for eligible survivors and 73% (243/332) for eligible controls. Median time from treatment to follow-up was 5 years (range, 1–14 years). Among the 21 investigated symptoms reflecting obstruction, frequency, urgency, pain and incontinence, we found significantly higher prevalence compared with controls for 9 symptoms in the EBRT group, 10 in the EBRT+brachytherapy group and 5 in the salvage EBRT group. The prevalence for a majority of the symptoms was stable over time. CONCLUSION: The presented toxicity profiles provide a thorough understanding of patient-reported urinary symptoms that can assist in developing personalised therapy for prostate cancer. Nature Publishing Group 2013-05-28 2013-04-30 /pmc/articles/PMC3670502/ /pubmed/23632483 http://dx.doi.org/10.1038/bjc.2013.180 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Clinical Study Olsson, C E Pettersson, N Alsadius, D Wilderäng, U Tucker, S L Johansson, K-A Steineck, G Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy |
title | Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy |
title_full | Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy |
title_fullStr | Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy |
title_full_unstemmed | Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy |
title_short | Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy |
title_sort | patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670502/ https://www.ncbi.nlm.nih.gov/pubmed/23632483 http://dx.doi.org/10.1038/bjc.2013.180 |
work_keys_str_mv | AT olssonce patientreportedgenitourinarytoxicityforlongtermprostatecancersurvivorstreatedwithradiationtherapy AT petterssonn patientreportedgenitourinarytoxicityforlongtermprostatecancersurvivorstreatedwithradiationtherapy AT alsadiusd patientreportedgenitourinarytoxicityforlongtermprostatecancersurvivorstreatedwithradiationtherapy AT wilderangu patientreportedgenitourinarytoxicityforlongtermprostatecancersurvivorstreatedwithradiationtherapy AT tuckersl patientreportedgenitourinarytoxicityforlongtermprostatecancersurvivorstreatedwithradiationtherapy AT johanssonka patientreportedgenitourinarytoxicityforlongtermprostatecancersurvivorstreatedwithradiationtherapy AT steineckg patientreportedgenitourinarytoxicityforlongtermprostatecancersurvivorstreatedwithradiationtherapy |